Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda, Keio, Niigata Univs in Tripartite Research Pact on RNA-Binding Proteins
April 21, 2015
- AbbVie’s Hepatitis C Drug Gets Priority Review in Japan
April 20, 2015
- Nicholas Grund to Come Back as Genzyme Japan President after 8 Months
April 20, 2015
- Takeda’s iPS Cell Deal Potential Game Changer in Drug Research
April 20, 2015
- 60% of 56 Drug Makers Increase Hiring of New Graduates in FY2015; Eisai Resumed Hiring
April 20, 2015
- Ajinomoto to Resume Hiring New Graduates: FY2016 Recruitment Plan
April 20, 2015
- Baxter Files NDA for Advate Successor in Japan
April 17, 2015
- Autologous Cultured Cartilage JACC Becomes Available Across Japan: J-TEC
April 17, 2015
- Takeda Hooks Up with Prof. Yamanaka on iPS Cell Research
April 17, 2015
- Japan’s Generic Market Projected to Top 900 Billion Yen in 2017: Fuji Keizai
April 16, 2015
- JCR Successfully Develops Blood-Brain Barrier-Passing Technology; First Application to Be Drug for Hunter Syndrome
April 16, 2015
- NIID, ID Pharma to Collaborate on Research for Therapeutic Vaccines for AIDS
April 16, 2015
- Nesina’s Cardiovascular Profile Acceptable: FDA Advisory Panel
April 16, 2015
- Lixiana Gains Swiss Nod, First Approval in Europe: Daiichi Sankyo
April 16, 2015
- MSD, Astellas to Develop Januvia-Suglat Combination Drug
April 16, 2015
- Hisamitsu Initiates PIII Study of Transdermal Parkinson’s Disease Treatment Ropinirole in Japan
April 16, 2015
- Eisai to Collaborate with Genomics for Drug Discovery
April 14, 2015
- Japan CSO Association Aims to Double No. of Contract Sales Reps to 8,000 by FY2020
April 14, 2015
- ViiV Healthcare Launches HIV Treatment Triumeq Combination Tablets
April 13, 2015
- Japan Vaccine Files NDA for Intradermal Influenza Vaccine
April 13, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…